drugset / Trial / NCT04357522

Immunogenicity and Safety Study of 15-Valent Pneumococcal Conjugate Vaccine in 2-month-old and 3-month-old Healthy Volunteers

NCT04357522

Phase 3 Unknown 1950 enrolled Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The purpose of this study is to evaluate Immunogenicity and safety of 15-Valent Pneumococcal Conjugate Vaccine in healthy volunteers aged 2 and 3 months.

Timeline

Start
2020-07
Primary completion
2026-03
Completion
2026-03

Drugs

EvaluationDrugModalityDoseRoute
Subject 15-Valent Pneumococcal Conjugate Vaccine Vaccine 0.5 ml Intramuscular
Comparator Prevnar 13 Vaccine 0.5 ml Intramuscular